
-
Israel pounds Iran from west to east in deepest strikes yet
-
Gezora wins Prix de Diane in Graffard masterpiece
-
Pogacar wins first Dauphine ahead of Tour de France title defence
-
Trump due in Canada as G7 confronts Israel-Iran crisis
-
Kubica steers Ferrari to third consecutive 24 Hours of Le Mans
-
French Open champ Alcaraz ready for Queen's after Ibiza party
-
India a voice for Global South at G7, says foreign minister
-
Tens of thousands rally in Dutch protest for Gaza
-
Sinner had 'sleepless nights' after dramatic French Open final loss
-
Gattuso named new Italy coach after Spalletti sacking
-
Relatives lament slow support, wait for remains after India crash
-
Israel vows to make Iran pay 'heavy price' as fighting rages on
-
Macron, on Greenland visit, berates Trump for threats against the territory
-
Qualifier Maria completes fairytale run to Queen's title
-
Gattuso named new Italy coach
-
Tens of thousands rally in Dutch Gaza protest
-
Israel-Iran conflict: latest developments
-
Israel keeps up Iran strikes after deadly missile barrage
-
Ex-president Sarkozy stripped of France's top honour after conviction
-
Iran missiles kill 10 in Israel in night of mutual attacks
-
'This is a culture': TikTok murder highlights Pakistan's unease with women online
-
Families hold funerals for Air India crash victims
-
US Fed set to hold rates steady in the face of Trump pressure
-
Iran launches missile barrage as Israel strikes Tehran
-
Sober clubbing brews fresh beat for Singapore Gen Z
-
Cummins flags Australia shake-up after WTC defeat as Ashes loom
-
Mexico down Dominican Republic to open Gold Cup defence
-
Pochettino defends Pulisic omission: 'I'm not a mannequin'
-
Panthers on brink of Stanley Cup repeat after 5-2 win over Oilers
-
Messi denied late winner in Club World Cup opener
-
Trump flexes military might at parade as protests sweep US
-
New-look Man City crave winning feeling at Club World Cup
-
Big tech on a quest for ideal AI device
-
Guest list for G7 summit tells of global challenges
-
Macron to Greenland in show of support after Trump threats
-
'Mass grave' excavation to finally start at Irish mother and baby home
-
'Hidden treasure': Rare Gandhi portrait up for UK sale
-
Fearless Chiefs plot raid on Crusaders fortress in Super Rugby final
-
US Open leader Burns eyes first major title at historic Oakmont
-
Messi gets Club World Cup under way in Miami
-
Burns grabs US Open lead with Scott and Spaun one back
-
Future of Uncrewed Airpower on Display at Paris Air Show
-
Trump basks in birthday military parade as protests sweep US
-
Russell grabs dazzling Canadian GP pole then jokes at Verstappen's expense
-
Thompson in six-way tie for LPGA lead in Michigan
-
Inter striker Taremi stranded in Iran amid conflict: club
-
No.1 Scheffler well back as pal Burns fights for US Open title
-
Trump's military parade kicks off as protests sweep US
-
PSG excitement for Club World Cup trumps fatigue ahead of Atletico clash
-
Iran launches more missiles as Israel targets Tehran

Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
F.AbuZaid--SF-PST